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Smacmimetics induce apoptosis synergistically with
TNF-a by triggering the formation of a caspase-8-
activating complex containing receptor interacting
protein kinase-1 (RIPK1). Caspase inhibitors block
this form of apoptosis in many types of cells.
However, in several other cell lines, caspase inhibitors
switch the apoptotic response to necrosis. A genome
wide siRNA screen revealed another member of the
RIP kinase family, RIP3, to be required for necrosis.
TheexpressionofRIP3 indifferent cell linescorrelates
with their responsiveness to necrosis induction. The
kinase activity of RIP3 is essential for necrosis execu-
tion. Upon induction of necrosis, RIP3 is recruited to
RIPK1 to form a necrosis-inducing complex. Embry-
onic fibroblasts from RIP3 knockout mice are resis-
tant to necrosis and RIP3 knockout animals are
devoid of inflammation inflicted tissue damage in an
acute pancreatitis model. These data indicate RIP3
as the determinant for cellular necrosis in response
to TNF-a family of death-inducing cytokines.
INTRODUCTION
Programmed cell death is executed through specific intracellular
biochemical pathways. Apoptosis and necrosis are two common
forms of programmed cell death that play essential roles in
development and maintaining homeostasis in metazoan animals
(Festjens et al., 2006). Defects in apoptosis and necrosis have
been implicated in the etiology of many forms of human diseases
(Lockshin and Zakeri, 2007).
Apoptosis is executed by a group of intracellular cysteine
proteases, namely caspases (Thornberry and Lazebnik, 1998).
Upon caspase activation and subsequent cleavage of intracel-
lular substrates, cells break into small membrane-wrapped vesi-
cles known as apoptotic bodies (Kerr et al., 1972). Necrosis, on
the other hand, is associated with organelle swelling, cyto-1100 Cell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc.plasmic membrane breakdown, and ensuing inflammation
responses (Festjens et al., 2006).
Caspase activation during apoptosis is accomplished through
two well-characterized pathways. The extrinsic pathway is acti-
vated through the binding of various death-inducing cytokines
including TNF-a, TRAIL, and CD95 ligand to their respective
receptors leading to the activation of caspase-8 (Peter and
Krammer, 2003); The intrinsic pathway is activated after mito-
chondrial intermembrane space proteins such as cytochrome
c and Smac/Diablo are released into the cytosol where they acti-
vate caspase-9 and relieve inhibition imposed by the Inhibitors of
apoptosis proteins (IAPs), respectively (Li et al., 1997; Du et al.,
2000; Verhagen et al., 2000). Activated caspase-8 and cas-
pase-9 subsequently cleave and activate several downstream
caspases, including caspase-3 and caspase-7, which then
cleave intracellular substrates, resulting in apoptosis.
These two pathways crosstalk through defined protein
networks. The extrinsic apoptotic signal is amplified by the
intrinsic pathway via the cleavage of Bid by caspase-8 (Li
et al., 1998; Luo et al., 1998). The truncated Bid, tBid, moves
from the cytosol to mitochondria and causes the release of
apoptogenic factors from mitochondria. On the other hand,
Smac protein, once left mitochondria, induces the auto-degra-
dation of cIAP1 and cIAP2, accelerating the formation of
a RIPK1-containing caspase-8 activating complex in response
to death receptor activation (Wang et al., 2008).
Interestingly, the same apoptosis-inducing cytokines also
cause necrosis in certain cell lines, especially when caspases
are inhibited or cannot be activated efficiently (Laster et al.,
1988; Vercammen et al., 1998a). In mouse fibrosarcoma L929
cells for example, TNF-a prominently causes necrosis instead
of apoptosis. In human T cell leukemia Jurkat cells that are
defective in caspase-8 activation adaptor protein FADD, activa-
tion of TNF receptor or CD95 resulted in necrosis (Chan et al.,
2003). The mechanism of TNF-a-induced necrotic cell death is
not well understood although both lysosomal and mitochondrial
dysfunction have been implicated (Festjens et al., 2006).
One essential protein in TNF-a, TRAIL, and CD95 ligand-
induced necrotic cell death is RIPK1 (Holler et al., 2000). RIPK1
is a multi-functional protein also known to mediate NF-kB and
caspase-8 activation in response to TNF-a (Hsu et al., 1996;
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Figure 1. A Smac Mimetic Plus a Pan-Cas-
pase Inhibitor Induce Necrosis in HT-29
Cells
(A and B) HT-29 colon cancer cells were treated
with DMSO, 100 nM Smac mimetic, 20 mM z-VAD
and/or 10 mM Necrostatin-1 for 48 hr. Identical
concentrations were used in later experiments
unless otherwise stated. Cell viability was deter-
mined by methylene blue staining (A) or by
measuring ATP levels using Cell Titer-Glo kit (B).
Data are represented as mean ± standard devia-
tion of duplicates. Abbreviations are as follows:
D, DMSO; S, Smac mimetic; Z, z-VAD; N, Necros-
tatin-1.
(C) HT-29 cells were treated with Smac mimetic for
the indicated time. Cell lysates were collected and
aliquots of 40 mg were subjected to western blot
analysis of cIAP1, cIAP2 and b-actin levels.
(D) HT-29 cells were treated as indicated for 48 hr.
Cells were analyzed for PI staining by flow cytom-
etry. All experiments were repeated at least three
times with similar results.
(E) Electron microscopy of HT-29 cells treated for
48h with DMSO or Smac mimetic plus z-VAD.
Black arrowheads denote cell membrane integrity
in the DMSO- treated cells and membrane break-
down in the cells treated with Smac mimetic plus
z-VAD. White arrowheads denote the swelling of
cellular organelles in the cells treated with Smac
mimetic plus z-VAD. Among 200 cells countered,
56 of them showed morphology as that presented
in b, c, and d in Smac mimetic plus z-VAD treated
sample while only 7 such cells were seen in DMSO
treated sample.Kelliher et al., 1998; Petersen et al., 2007; Wang et al., 2008).
Although the kinase activity of RIPK1 is not required for NF-kB
activation, such activity is crucial for both caspase activation
and necrosis induction (Holler et al., 2000; Wang et al., 2008).
ThenecrosiseffectorofRIPK1 isunknown.Neither is the relation-
ship between RIPK1 kinase-dependent apoptosis and necrosis.
Moreover, why certain cells such as L929 and Jurkat are able to
undergo necrotic death in response to TNF-a family of cytokines
while others solely commit to apoptosis remains a mystery.
Our laboratory has been studying cellular apoptotic pathways
using a small molecule that mimics the function of Smac protein
(Li et al., 2004). Our study revealed that the Smac mimetic
together with TNF-a, promote the formation of a caspase-8-acti-
vating complex consisting of RIPK1, FADD, and caspase-8 (Pe-
tersen et al., 2007; Wang et al., 2008). During these studies, we
noticed that the Smac mimetic-induced cell death in human
colon cancer HT-29 cells could not be blocked by pan-caspase
inhibitors as in many other types of cells. Instead, HT-29 cells
underwent massive necrosis. A systematic analysis of this form
of cell death using a combination of genome-wide siRNA
screening and biochemical investigation revealed that a member
of the receptor-interacting kinases, RIP3, is the key determinant
for necrotic cell death downstream of RIPK1.RESULTS
A Smac Mimetic Plus a Pan-Caspase Inhibitor Induce
Necrosis in HT-29 Cells
Smac mimetics have been shown to induce apoptosis in certain
tumor cell lines (Petersen et al., 2007; Vince et al., 2007; Varfolo-
meev et al., 2007), and death can be completely blocked with
a pan-caspase inhibitor, z-VAD. Surprisingly, in HT-29 cells,
exacerbated cell death occurred when cells were treated with
Smac mimetic plus z-VAD (Figures 1A and 1B) or another pan-
caspase inhibitor Q-VD-OPH (Figure S1). Consistent with
previous reports, both cIAP1 and cIAP2 in HT-29 cells underwent
accelerated degradation upon Smac mimetic treatment
(Figure 1C). Unlike apoptotic death, these dying cells showed
positive propidium iodide (PI) staining (Figure 1D) and cell death
was prevented by a necrosis specific chemical inhibitor, Necros-
tatin-1 (Figures 1A and 1B, Degterev et al., 2005).
To verify that cell death seen in HT-29 cells was indeed
necrosis, cells treatedwitheither vehicleDMSO,orSmacmimetic
plus z-VAD, were analyzed by electron microscopy (EM). While
most of DMSO treated cells showed normal cellular morphology
including intact cytoplasmic membranes (Figure 1E-a), a signifi-
cant percentage of cells treated with Smac mimetic/z-VADCell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc. 1101
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BA Figure 2. TNF-a and RIPK1 Are Required for
SmacMimetic Plus z-VAD Induced Necrosis
(A) HT-29 cells were treated with PBS or TNF-a
neutralizing antibody at indicated concentrations
for 1 hr prior to the treatment of DMSO or Smac
mimetic plus z-VAD for additional 48 hr. Cell
viability was determined by measuring ATP levels.
Data are represented as mean ± standard devia-
tion of duplicates.
(B) HT-29 cells were transfected with the control or
TNF-RI siRNAs. Forty-eight hours posttransfec-
tion, cells were treated as indicated for additional
48 hr and then cell viability was determined by
measuring ATP levels. Data are represented as
mean ± standard deviation of duplicates.
(C) The knockdown efficiency of TNF-RI RNAi Cell
lysates were collected 48 hr posttransfection and
aliquots of 40 mg were subjected to western blot
analysis of TNF-RI and b-actin levels. The asterisk
denotes a crossreactive band.
(D) HT-29 cells were treated with DMSO, Smac
mimetic/z-VAD or TNF-a (20 ng/ml)/ Smac
mimetic/z-VAD for 48 hr. Cell viability was deter-
mined by measuring ATP levels. Data are repre-
sented asmean± standard deviation of duplicates.
Identical concentration of TNF-a was used in later
experiments unless otherwise stated.
(E) HT-29 cells were transfected with the control or
RIPK1 siRNAs. Forty-eight hours posttransfection,
cells were treated as indicated for additional 48 hr.
Cell viability was determined by measuring ATP
levels. Data are represented as mean ± standard
deviation of duplicates.
(F) The knockdown efficiency of RIPK1 RNAi. Cell
lysates were collected 48 hr posttransfection and
aliquots of 40 mg were subjected to western blot
analysis of RIPK1 and b-actin levels. All experi-
ments were repeated at least three times with
similar results.displayed swelled mitochondria as well as discontinuous cyto-
plasmic membranes (Figure 1E-b, c, d). No obvious apoptotic
morphological changes were observed.
Smac Mimetic Plus z-VAD Induced Necrosis Requires
TNF-a and RIPK1
Since Smac mimetic induces apoptosis in certain tumor lines as
a result of autocrine TNF-a (Petersen et al., 2007; Vince et al.,
2007; Varfolomeev et al., 2007), we checked whether autocrine
TNF-a is required for the observed necrosis in HT-29 cells.
Indeed, addition of an increasing amount neutralizing anti-TNF-a
antibody to the culture medium blocked this form of cell death
(Figure 2A). Consistently, knockdown of TNF receptor I also pre-
vented these cells from dying (Figures 2B and 2C). Moreover,
exogenously added TNF-a augmented Smac mimetic plus
z-VAD induced cell death (Figure 2D) and it did so in a dose
dependent manner (Figure S2 available with this article online).
Since RIPK1 is a critical mediator for TNF-a induced necrosis
(Holler et al., 2000), we also checked if the observed Smac
mimetic-induced necrosis required RIPK1. As shown in Figures
2E and 2F, knockdown of RIPK1 almost abolished this form of
cell death.1102 Cell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc.A Genome-Wide siRNA Screening Revealed RIP3
Is Critical for Necrosis
The fact that Smac mimetic induced cell death requires both
TNF-a and RIPK1 and that cell death was blocked by Necrosta-
tin-1 indicated that such a form of cell death is similar to the
previously described phenomenon of programmed necrosis or
necropotosis (Holler et al., 2000; Lin et al., 2004; Degterev
et al., 2008). The finding that Smac mimetic drastically promoted
z-VAD and TNF-a induced necrosis, however, offered us a more
robust necrotic death system to further dissect the signaling
pathway for necrosis.
We took advantage of this necrotic cell death model and
performed a genome-wide siRNA screen using a Dharmacon
human siRNA library consisting of 22,000 pools of four siRNA oli-
goes. Pools of siRNA were transfected into HT-29 cells cultured
in 96-well plates, which were subsequently treated with TNF-a,
Smac mimetic, and z-VAD. Exogenous TNF-a was added to
increase the signal to noise ratio, and to rule out any siRNAs
affecting TNF-a secretion. Cell viability was then measured
and the ratio of viability between cells treated with these agents
versus those treated with DMSO was scored. A siRNA oligo
targeting RIPK1 was used as the positive control.
BA
D
C
E F
Figure 3. RIP3 and Its Kinase Activity Are
Required for the TNF-a, Trail, and Fas
Ligand-Induced Necrosis but Not Apoptosis
(A) Protein domain structure of the top two hits
from a genome-wide siRNA screening: RIPK1
and RIP3. RHIM: RIP homotypic interaction motif;
DD: Death domain. Genome-wide siRNA
screening was performed as described in the
Experimental Procedures. Screening results were
scored as the ratio of survived cells treated with
TNF-a/Smac mimetic/z-VAD versus treated with
DMSO.
(B) HT-29 cells, RIP3-shRNA, WT-RIP3 or RIP3-
K50A stable cells were generated as described in
the Experimental procedures and treated with
DMSO or TNF-a/Smac mimetic/z-VAD for 48 hr.
Cell viability was determined by measuring ATP
levels. Data are represented as mean ± standard
deviation of duplicates. RIP3-shRNA: HT-29 cells
stably expressing a shRNA targeting RIP3;
WT-RIP3: RIP3-shRNA cells stably expressing
a shRNA-resistant wild-type form of RIP3; RIP3-
K50A: RIP3-shRNA cells stably expressing
a shRNA-resistant RIP3 kinase dead mutant.
(C) Cell lysates were collected from indicated cells
and aliquots of 40 mg were subjected to western
blot analysis of RIP3, RIPK1, and b-actin levels.
(D) HT-29 cells or RIP3-shRNA stable cells were
treated as indicated for 8 hr. Cell lysates were
collected and aliquots of 40 mg were subjected to
western blot analysis of PARP and b-actin levels.
C, cycloheximide (10 mg/ml).
(E) HT-29 cells or RIP3-shRNA stable cells were
treated as indicated for 24 hr. Cell viability was
determined by measuring ATP levels. Data were
represented as mean ± standard deviation of
duplicates.
(F) HT-29 cells or RIP3-shRNA stable cells were
treated with DMSO, Smac mimetic/z-VAD, or
TRAIL (200ng/ml)/Smac mimetic/z-VAD or
FasL(200ng/ml)/Smac mimetic/z-VAD for 48 hr.
Cell viability was determined by measuring ATP
levels. Data are represented as mean ± standard
deviation of duplicates.
All experiments were repeated at least three times
with similar results.As a validation to our screening strategy, the top hit with
a score of 0.72 turned out to be RIPK1. The second best hit,
with a score of 0.65, is another member of RIP kinase family,
RIP3 (Figure 3A). RIP3 shares close similarity with RIPK1 at its
N-terminal kinase domain and C-terminal RHIM domain through
which it interacts with RIPK1 (Figure 3A; Sun et al., 1999, 2002;
Yu et al., 1999). Unlike RIPK1, RIP3 does not have the death
domain at its C terminus.
RIP3 and Its Kinase Activity Are Required for Necrosis
but Not Apoptosis
To verify the role of RIP3 in necrosis, a cell line that stably ex-
pressed a shRNA targeting RIP3was generated from the parental
HT-29 cells. As shown in Figures 3B and 3C, compared to its
parental cells, cells with RIP3 knockdown were resistant to
necrosis.WhenRIP3expressionwas restoredwithashRNA resis-
tant RIP3 transgene, cell death was re-established. However, ifthe transgene contains a K50A mutation known to abolish its
kinase activity, cell death remained blocked. The observed differ-
ence in cell death was not due to changes in RIPK1 since its level
remained the same in all four cell lines (Figure 3C).
We then tested whether RIP3 also has a role in apoptosis by
measuring the cleavage of poly(ADP)ribose polymerase
(PARP), a caspase-3/7 substrate, and cell survival rates between
parental and RIP3 shRNA expressing HT-29 cells. No difference
was seen in PARP cleavage or cell survival in these cells when
apoptosis was induced by TNF-a plus Smac mimetic or cyclo-
heximide (Figures 3D and 3E). In addition to TNF-a, Trail and
CD95/Fas ligand have also been shown to be able to induce
necrosis (Vercammen et al., 1998b; Holler et al., 2000). To test
whether RIP3 is also required for Trail and CD95-induced
necrosis, we treated the same pair of parental and RIP3 shRNA
expressing HT-29 cells with Trail/Smac mimetic/z-VAD or Fas
ligand/Smac mimetic/z-VAD. As shown in Figure 3F, cell deathCell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc. 1103
induced by these agents was also completely eliminated in the
RIP3 knockdown cells.
The Expression of RIP3 Correlates with Cellular
Necrotic Response
To further confirm the role of RIP3 in TNF-a-induced necrosis,
we treated 13 other cell lines with TNF-a, Smac mimetic, and
z-VAD. We then measured cell viability and the level of RIP3 in
these cell lines. As shown in Figures 4A and 4B, five cell lines
including human T cell leukemia Jurkat and CCRF-CEM cells,
human monocytic leukemia U937 cells, mouse fibrosarcoma
L929 cells, and mouse embryonic fibroblasts (MEFs) responded
to the treatment and underwent necrosis. All these cells ex-
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Figure 4. The Expression of RIP3 Correlates
with Their Necrotic Response
(A) The indicated cell lineswere treatedwith DMSO
or TNF-a/Smac mimetic/z-VAD for 48 hr. Cell
viability was determined by measuring ATP levels.
Data are represented as mean ± standard devia-
tion of duplicates.
(B) Cell lysates from indicated cells were collected
and aliquots of 40 mg were subjected to western
blot analysis of RIP3, RIPK1 and b-actin levels.
(C) L929 cells were transfected with control or
mRIP3-1 siRNAs. Forty-eight hours posttransfec-
tion, cells were treated as indicated for additional
48 hr. Cell viability was determined by measuring
ATP levels. Data are represented as mean ± stan-
dard deviation of duplicates.
(D) The knockdown efficiency of RIP3 RNAi. Cell
lysates were collected 48 hr posttransfection and
aliquots of 40 mg were subjected to western blot
analysis of RIP3 and b–actin levels.
(E) T98G glioblastma cells were transfected with
vector or plasmid DNA expressing wild-type RIP3
(WT-RIP3) or RIP3 kinase dead mutant (RIP3-
K50A). Forty-eight hours posttransfection, cells
were treated as indicated for another 48 hr. Cell
viability was determined by measuring ATP levels.
Data are represented as mean ± standard devia-
tion of duplicates. Cell lysates were collected
48 hr posttransfection and aliquots of 20 mg were
subjected to western blot analysis of RIP3,
RIPK1 and b-actin levels.
All experiments were repeated at least three times
with similar results.
pressed RIP3. On the other hand, human
cervical cancer HeLa cell, breast cancer
MCF-7 cell, osteosarcoma U2OS cell,
glioblastoma T98G cell, pancreatic
cancer Panc-1 cell, nonsmall cell lung
cancer NCI-460 and H2009 cells, as well
as embryonic kidney 293T cells did not
express any detectable RIP3 and they
did not undergo cell death upon these
treatments. Unlike RIP3, RIPK1 was ubiq-
uitously expressed in all these cells.
TNF-a induced necrosis has been most
extensively studied inmouse fibrosarcoma
L929 cells due to its unique ability to undergo necrosis in response
to TNF-a, or z-VAD alone (Vercammen et al., 1998b; Degterev
et al., 2005; Kim et al., 2007). To test whether RIP3 is required for
necrosis in this L929 cells, we knocked downRIP3with three indi-
vidual mouse siRNA oligoes. The result of one such oligo is shown
inFigures4Cand4D.Cell death inducedbyz-VAD,orTNF-aalone
orcombinationof the twowasattenuatedwhenRIP3wasknocked
down in L929 cells. The efficacy of necrosis blockage of these oli-
goes correlated with the efficiency of RIP3 knockdown (Figures
S3A and S3B). The levels of RIPK1 in L929 cells did not change
after RIP3 was knocked down (Figure S3B). Similar to HT-29 cells,
necrotic cell death in L929 cells was also accelerated by Smac
mimetic in a concentration dependent manner (Figure S3C).1104 Cell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc.
Since cells resistant to TNF-a induced necrotic death are also
defective in RIP3 expression, we then tested whether ectopic
expression of RIP3 converts these cells to sensitive ones. As
shown in Figures 4E and 4F, whenwild-type RIP3was expressed
in T98G cells at a sub-toxic level, we saw marked cell death in
these cells upon necrosis induction compared to vector trans-
fection controls. Expression of the kinase dead K50A mutant
RIP3, however, did not cause cell death. Moreover, cell death
in T98G cells resulted from RIP3 expression was blocked by
the necrosis inhibitor, Necrostatin-1 but not caspase inhibitor
zVAD, indicating that the observed cell death is necrosis. Similar
effects were observed when RIP3 was expressed in HeLa cells,
MCF-7 cells, and H2009 cells (Figure S4).
RIP3 Kinase-Dead Mutant Dominant Negatively
Regulates Necrosis
To study how RIP3 induce necrosis, we first tested whether the
kinase dead mutant of RIP3 functioned as a dominant negative
mutant by stably expressing the K50A mutant of RIP3 in HT-29
cells. Expression of RIP3 (K50A) at a level above the endogenous
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Figure 5. Kinase-Dead Mutant of RIP3
Behaves as Dominant-Negative Regulator
of Necrosis
(A) HT-29 cells or HT-29 cells stably expressing
flag-tagged RIP3 kinase dead mutant (RIP3-
K50A) were treated with DMSO or TNF-a/Smac
mimetic/z-VAD for 48 hr. Cell viability was deter-
mined by measuring ATP levels. Data were repre-
sented asmean± standard deviation of duplicates.
(B) Cell lysates from both cell lines were collected
and aliquots of 40 mg were subjected to western
blot analysis of RIP3 and b-actin levels.
(C) HT-29 RIP3-K50A expressing stable line was
transfectedwith indicatedsiRNAs.Forty-eighthours
posttransfection, cells were treated with DMSO or
TNF-a/Smac mimetic/z-VAD for additional 48 hr.
Cell viability was determined by measuring ATP
levels. Data were represented as mean ± standard
deviation of duplicates. RIP3-1-S and RIP3-1 siR-
NAs were designed to specifically knockdown
Flag-RIP3 and endogenous RIP3, respectively.
(D) The RNAi efficiency of RIP3-1 and RIP3-1-S
siRNA. Cell lysates were collected 48 hr posttrans-
fection and aliquots of 40 mg were subjected to
western blot analysis of RIP3 and b-actin levels.
(E and F) HT-29 RIP3-K50A expressing stable cells
were treated as indicated and aliquots of 1 mg of
cell lysates were immunoprecipitated with anti-
Flag beads (E), or RIPK1 antibody or control IgG
(F). The immunocomplex was eluted with Flag
peptide (E) or acid (F) in 60 ml volume and the
whole elution was used to measure Flag-RIP3
and RIPK1 levels by western blot analysis.
All experiments were repeated at least two times
with similar results.
RIP3 blocked Smac mimetic/z-VAD or
Smacmimetic/z-VADplus TNF-a induced
cell death (Figures 5A and 5B).
To verify the blockage of cell death was
indeed due to the dominant negative
effect of RIP3 K50A mutant expression, we designed siRNA
that specifically knocked down the mutant form of RIP3. Indeed,
knockdown of this kinase dead form of RIP3 restored the cell
death response as long as the endogenous RIP3 remained intact
(Figures 5C and 5D).
The dominant negative effect of RIP3 kinase deadmutant sug-
gested that this protein might bind and sequester other signaling
molecule in this necrosis pathway. The obvious candidate would
be RIPK1. To test this directly, we immunoprecipitated RIP3
K50A from the HT-29 cells that stably expressed this transgene
and the immune complexwas analyzed bywestern blotting using
an anti-RIPK1 antibody. As shown in Figure 5E, noRIPK1was co-
precipitatedwith the kinasedeadRIP3up to 8hr of treatmentwith
TNF-a alone, or TNF-a plus Smac mimetic or z-VAD. However,
4 hr after treatment of all three agents together, RIPK1was found
in the RIP3 K50A precipitate and the amount increased at 6 and
8 hr of treatment. The interaction between RIPK1 and RIP3
mutant was verified with reciprocal pull down with an anti-
RIPK1 antibody (Figure 5F). Again, the two proteins interacted
only when all three necrosis-inducing agents were present.Cell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc. 1105
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Figure 6. RIP3 Forms Complex with RIPK1 Only upon Necrotic Induction
(A) HT-29 or HT-29 RIP3-shRNA stable cells were treated as indicated. Aliquots of 4 mg of cell lysates were immunoprecipitated with RIPK1 antibody or control
IgG as described in the Experimental Procedures. The RIPK1 immunocomplex was eluted with acid in 60 ml volume and the whole elution was used to measure
the levels of RIP3 and RIPK1 in the immunocomplex by western blot analysis.
(B) HT-29 cells stably expressing flag-tagged wild-type RIP3 were treated as indicated for 8 hr. Aliquots of 1 mg of cell lysates were prepared for immunopre-
cipitation using an anti-Flag antibody. The levels of RIP3 and RIPK1 in the immunocomplex were determined by western blot analysis.
(C and D) T98G cells were transfected with vector, or plasmid DNA expressing Flag-tagged wild-type RIP3 (WT-RIP3), RIP3 kinase dead mutant (RIP3-K50A),
or RIP3-AAAA (residues 459-462 mutated to AAAA). Forty-eight hours posttransfection, cells were treated for 48 hr as indicated. Cell viability was determined by
measuring ATP levels (C). Data are represented as mean ± standard deviation of duplicates. Cell lysates were collected and aliquots of 20 mg were subjected to
western blot analysis of RIP3, RIPK1, and b-actin levels (D).
(E) HT-29 cells stably expressing flag-RIP3 were treated with DMSO/TNF-a (100 ng/ml)/Smac mimetic/z-VAD or Necrotatin-1/TNF-a/Smac mimetic/z-VAD.
At the indicated time points, cell lysates were collected and aliquots of 500 mg total cell extracts were immunoprecipitated with an anti-caspase-8 antibody
as described in Wang et al., 2008. The caspase-8 immunocomplex was eluted with acid in 40 ml volume and the whole elution was used to measure the levels
of flag-RIP3, RIPK1, caspase-8, and FADD by western blot analysis.
All experiments were repeated at least two times with similar results.RIP3 Forms a Necrotic Complex with RIPK1
The dominant negative effect of kinase dead mutant RIP3 sug-
gested that it might sequester RIPK1 and prevent its interaction
with endogenous RIP3. To test whether endogenous RIP3
indeed interacts with RIPK1 upon necrosis induction, we treated
HT-29 cells with TNF-a, Smac mimetic and z-VAD, followed by1106 Cell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc.immunoprecipitation using an anti-RIPK1 antibody at different
time points. Interestingly, an up-shift of RIP3 was observed after
4 hr of treatment and the shifted RIP3 continued to increase up to
8 hr (Figure 6A, left panel). Correlating with the shift, RIP3 was
found in the RIPK1 immunocomplex starting at 4 hr of necrosis
induction and peaked at 8 hr (Figure 6A, right panel). The up-shift
of RIP3 and its interaction with RIPK1 only occurred under
necrosis-inducing conditions (Figure S5A). The observed up-
shift of RIP3 is due to phosphorylation at the Ser199 site that
depends on its own kinase activity. No such shift was observed
in RIP3 K50Amutant protein when it was pulled downwith RIPK1
(Figures 5E and 5F). Moreover, the RIP3 band can be shifted
down to the original position on SDS-PAGE gel with a phospha-
tase treatment or a Ser199 to Ala mutation (Figures S5B and
S5C).
To further confirm the relevance of RIP3 up-shift and its
induced interaction with RIPK1 to necrosis, HT-29 cells were
cotreated with Necrostatin-1 during necrosis induction. As
shown in Figure 6B, cotreatment with Necrostatin-1 completely
prevented RIP3 up-shift as well as its interaction with RIPK1.
The importance of RIP3 and RIPK1 interaction for necrosis
induction was verified with a mutation at the RHIM domain of
RIP3 that is known to abolish its ability to interact with RIPK1
(Sun et al., 2002; Figure S6). Similar to the kinase dead mutant,
introductionof thismutantproteinwasunable to renderT98Gcells
responsiveness to the necrosis induction (Figures 6C and 6D).
Since RIPK1 forms a complex with caspase-8/FADD upon
treatment with TNF-a plus Smac mimetic and the complex is
stabilized by z-VAD (Petersen et al., 2007; Wang et al., 2008),
we wondered whether it is the same complex that recruits
RIP3. To check that directly, we immunoprecipitated caspase-
8 and analyzed the composition of the immunocomplex by
western blotting. As shown in Figure 6E, RIP3was found to asso-
ciate with the RIPK1/FADD/caspase-8 complex after 4 hr of
treatment. RIP3 continued to be recruited to the complex for
up to 6 hr of treatment. Much less proteins were immunoprecip-
itated at 8 hr with this anti-caspase-8 antibody. This observation
might reflect that a large percentage of cells were dying at this
time point. When cells were cotreated with Necrostatin-1, none
of these complexes were able to form efficiently. This is consis-
tent with the notion that Necrostatin-1 inhibits RIPK1 kinase
activity, which is required for the formation of RIPK1/FADD/cas-
pase-8 complex (Degterev et al., 2008; Wang et al., 2008).
To probe how RIP3 containing complex induces necrosis, we
measured cellular localization of RIP3 in HT-29 cells before and
after necrosis induction. RIP3 in resting cells is distributed in the
cytosol (Figure S7). Upon necrosis induction, it forms punctuated
and filamentary dots and rods reminiscent of some kinds of
organelle staining (Figure S7). However, costaining with intracel-
lular organelle markers, including mitochondria, nuclei, ER,
Golgi, lysosomes, endosomes, and peroxisomes, did not show
obvious colocalization (Figure S7). It is therefore unlikely that
the RIPK1/RIP3 necrosis complex simply destroys a cellular
organelle by directly targeting it.
RIP3 Knockout Mice Showed Less Tissue Damage
in a Cerulein-Induced Mouse Acute Pancreatitis Model
The fact that RIP3 is a critical mediator of TNF-a-induced
necrosis, yet is dispensable in animal development allowed us
to investigate this form of cell death in RIP3 knockout mice
(Newton et al., 2004). We reproduced RIP3 knockout mice as re-
ported in Newton et al. and studied its role under pathological
conditions in which necrotic cell death has been implicated
(Figure S8).We first verified the importance of RIP3 in TNF-a-induced
necrosis in embryonic fibroblasts (MEFs) prepared from
embryos of RIP3-/+ mating. As shown in Figure 7A, MEFs from
RIP3 knockout embryos did not contain any RIP3 protein while
heterozygote MEFs had roughly half of RIP3 as in wild-type
MEFs. RIPK1 level did not change in these cells. When these
cells were treated with necrosis inducing agents including
TNF-a/Smac mimetic/z-VAD or TRAIL/Smac mimetic/z-VAD,
MEFs from the wild-type animal committed to death while cells
from RIP3 knockout embryos did not (Figure 7B; Figures S9A
and S9B). It is interesting to note that theseMEFswere also quite
resistant to Trail plus Smac mimetic induced apoptosis.
However, the wild-type MEFs were readily killed when z-VAD
was included (Figure 7B). In contrast, no difference in apoptosis
was seen in RIP3 wild-type and knockout MEF when they were
treatedwith TNF-a plus cycloheximide (Figure S9C), an observa-
tion that agrees with what was reported in the original RIP3
knockout paper (Newton et al., 2004).
We chose cerulein-induced pancreatitis in mice to further
study the role of RIP3 in this necrosis-associated disease model.
Most cell death in the pancreas was found to be necrotic rather
than apoptotic and the degree of necrosis correlates with
severity of the disease (Mareninova et al., 2006). Interestingly,
when we analyzed the expression of RIP3 in different tissues
from the cerulein-treated animals, we noticed a dramatic
increase of RIP3 protein in the pancreas (Figure 7C). No such
increase was seen in other tissues including liver, brain, spleen,
and thymus. Twenty-four hours after the treatment, 8 out of 12
cerulein treated wild-type animals showed multiple areas of
pancreas acinar cell loss and necrosis (Figure 7D). This effect
was largely prevented in all RIP3 knockout littermates (n = 11).
Consistently, serum amylase was elevated to higher levels in
wild-type animals 24 hr after treatment of cerulein compared to
those in the RIP3 knockout littermates (Figure 7E).
DISCUSSION
RIP3 Represents a Key Switch Point in the TNF-a-
Induced Cellular Apoptotic and Necrotic Pathways
RIP3 had been an innocuous member of the RIP kinase family.
Although ectopic expression of RIP3 in mammalian cells has
been shown to cause apoptosis, such a phenotype could be
the result of artificially high expression (Yu et al., 1999; Sun
et al., 1999). Indeed, knockout of RIP3 in mice did not cause
any measurable defect in development, fertility, NF-kB activa-
tion, and apoptosis (Newton et al., 2004). In contrast, the found-
ing member of the RIP family, RIPK1, has critical roles in the
above-mentioned signaling pathways and RIPK1 knockout mice
die soon after birth (Kelliher et al., 1998; Holler et al., 2000; Pe-
tersen et al., 2007; Wang et al., 2008).
The pro-apoptotic function of RIPK1 is to form a caspase-8
activation complex in response to TNF Receptor I activation
(Wang et al., 2008). This process starts with the accelerated
degradation of cIAP1/2 induced by Smac protein (or Smac
mimetics), and proceeds with release of RIPK1 from the TNFRI,
deubiquitination of RIPK1 by the deubiquitin enzyme CYLD, and
subsequent recruitment of FADD and caspase-8 to RIPK1 (Wang
et al., 2008). The activation of caspase-8 in this complex resultsCell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc. 1107
in cleavage of RIPK1 by caspase-8 (Lin et al., 1999). The
cleavage of RIPK1 by caspase-8 potentially terminates necrotic
signal.
The work presented here indicated that RIP3 is also recruited
to the RIPK1 complex through direct interaction between the
RHIM domains of RIPK1 and RIP3. If caspase-8 is inhibited after
death receptor activation, RIP3 forms a stable complex with
RIPK1/FADD/caspase-8 (Figure 6E) and transforms it to a pro-
necrosis complex. The necrosis blocker Necrostatin-1 efficiently
prevents RIPK1/FADD/caspase-8 complex formation and
subsequent recruitment of RIP3 to the complex (Figure 6E).
Thus, apoptosis and necrosis induced by death inducing cyto-
kines share a common biochemical pathway down to the step
of RIPK1 activation following receptor activation, cIAP1/2 degra-
dation, and deubiquitination of RIPK1 by CYLD. It is thus not
surprising that CYLD is required for efficient RIPK1/FADD/cas-
pase-8 complex formation (Wang et al., 2008) and scored as
A
D
E
C
B Figure 7. RIP3-Dependent Necrosis in
a Cerulein-Induced Pancreatitis Model
(A) The MEF cells were isolated from RIP3+/+,
RIP3+/, and RIP3/ mice as described in the
Experimental Procedures. Cell lysates were
collected and aliquots of 40 mg were used to
measure for western blot analysis of RIP3,
RIPK1, and b-actin levels.
(B) RIP3+/+ or RIP3/ MEF cells were treated as
indicated for 24 hr. Recombinant mouse TRAIL
was used at 20 ng/ml. Cell viability was determined
by measuring ATP levels. Data are represented as
mean ± standard deviation of duplicates. Experi-
ment was repeated at least three times with similar
results.
(C–E) RIP3 knockout (n = 11) and wild-type litter-
matemice (n = 12) were given intraperitoneal injec-
tions of 50 mg/kg cerulein or saline once every hour
for 10 hr. Fourteen hours after the last injection,
mice were sacrificed and the samples of tissues
and blood were harvested. The proteins were ex-
tracted from indicated tissues and subjected to
western blot analysis of RIP3 and GAPDH levels
(C). (D) The pancreatic tissue was stained with
hematoxylin and eosin. The stained sections
were examined by a pathologist in a blind fashion.
Eight out of twelve cerulein treated wild-type
animals showed multiple areas of pancreas acinar
cell loss and necrosis while this effect was largely
prevented in all RIP3 knockout littermates (n = 11).
This effect is statistically significant (*p < 0.01).
(E) Serum amylase activity was measured using
amylase assay kit.
The result shown here are representative of five
animals.
the top hit in a genome-wise siRNA
screen in L929 cells for genes whose
knockdown prevented TNFa-mediated
necrosis (necropotosis) in these cells (Hi-
tomi et al., 2008).
The role of FADD in necrosis signaling
seems cell type specific. The MEFs from
FADD knockout mice are resistant to TNF-a-induced necrosis
(Lin et al., 2004) while FADD null Jurkat cells underwent necrosis
in response to TNF-a (Chan et al., 2003; Figures S10A and
S10C). The biochemical mechanism underlines such cell type
specificity should be an interesting topic for future studies.
Similar to HT-29 and L929 cells, the TNF-a-induced necrosis in
FADD null Jurkat cells was also drastically accelerated by the
Smac mimetic and the death was nearly abolished after RIP3
knockdown (Figures S10C and S10D). It is interesting to note
that necrotic death in these cells does not require the presence
of caspase inhibitors since there was no caspase-8 activation
upon TNF-a/Smac mimetic treatment in contrast to wild-type
Jurkat cells (Figure S10B).
The status of NF-kB also seems to affect cellular necrotic
response to TNF-a/Smac mimetic/z-VAD. Blockage of NF-kB
with an IKK inhibitor enhanced necrosis in HT-29 cells treated
with these agents (Figure S11). The mechanism of such1108 Cell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc.
enhancement should be another interesting topic for future
studies.
Mechanism of RIP3-Dependent Necrotic Cell Death
It remains puzzling how RIP3/RIPK1 complex induces necrosis.
Since RIP3 does not colocalize with all the major cell organelles
examined (Figure S7), it is unlikely that the RIP3/RIPK1 pro-
necrotic complex directly destroy them. It is possible that this
complex phosphorylates some specific cellular target(s) in
a necrotic pathway. Identifying the unknown components of
such a pathway should be an exciting topic for future studies.
Although not affected directly, mitochondria could be at least
one of the targets in this pathway.Mitochondria are the center for
energy production, Ca2+ buffering, and ROS production. Mal-
function of mitochondria will lead to collapse of the cell and
thus necrosis. Indeed, in THP-1 cells, ANT, the mitochondrial
ADP/ATP nucleotide exchanger, is locked into its cytosolic
configuration and is unable to carry out ADP/ATP exchange
when treated with TNF-a plus z-VAD (Temkin et al., 2006). Inac-
tivation of ANT stops oxidative phosphorylation-mediated ATP
generation, resulting in depletion of cellular energy pools and
necrotic cell death. Mitochondrial cyclophilin D, the regulator
of ANT, might be a target of necrosis inducers. Consistently,
MEFs from cyclophilin D knockout mice are partially resistant
to TNF-a, Smac mimetic plus z-VAD induced cell death,
although the resistance is not as complete as the RIP3 knockout
MEFs (Figure S12; Nakagawa et al., 2005).
Reactive oxygen species (ROS) have been implicated in
TNF-a-induced, RIPK1-dependent necrosis (Lin et al., 2004).
Nox1 NADPH oxidase has been shown to work downstream of
RIPK1 to generate ROS in L929 and MEF cells (Kim et al.,
2007). However, ROS dependence seems cell-type specific.
ROS quenching prevented necrosis in L929 cells but failed to
do so in HT-29 cells treated with TNF-a, Smac mimetic, and
z-VAD (data not shown). It seems that ROS is only required for
one of branches of the RIP3-dependent necrosis pathway.
Physiological and Pathological Significance
of Necrotic Death
Necrosis has often been associated with extreme physical-
chemical injury. Although TNF-a, CD95 ligand, or TRAIL induced
death receptor activation has been well documented to cause
necrosis in certain cells, the significance of necrosis remains to
be validated under physiological and pathological situations.
We tested the role of RIP3 in mouse models of cerulein-
induced pancreatitis. Interestingly, although big differences
between wild-type and RIP3 knockout mice were observed
24 hr after the first and 14 hr after the last cerulein injection,
similar tissue damage was seen in these animals 10 hr after
the first cerulein injection (data not shown), consistent with the
idea that it is not the initial injury that is RIP3 dependent. More
likely, the subsequent damages caused by the ensuing inflam-
matory response was eliminated in the pancreas of RIP3
knockout mice and the initial damage caused by the cerulein-
induced leakage of pancreatic digestive enzymes had recov-
ered. These results suggest that RIP3-dependent necrosis is
part of a defense system against tissue injury caused by physical
or chemical damage, and maybe more frequently, by microbeinfections. Necrotic death could be an important way to eliminate
damaged cells especially when caspases cannot be activated
efficiently, like in FADD null Jurkat cells, or is blocked. Unlike
apoptosis, necrosis amplifies the initial damage signal by acti-
vating inflammatory response, which further destroys the
damaged cells and facilitates the clean up of cell debris. Not
surprisingly, RIP3 expresses strongly in immunologic organs
like thymus and spleen and its expression is induced during
tissues injury (Figure 7C).
Other systems in which morphologically defined necrosis
occur include T lymphocytes after HIV-1 infection and neutro-
phils/macrophages after bacterial infection (Festjens et al.,
2006). In these cases, viruses and bacteria often carry their
own caspase inhibitors, and necrotic death may serve as an
important defense mechanism to eliminate the microbes and
solicit inflammation by releasing intracellular contents and/or
cytokines.
Necrosis, when run in excess, could potentially cause irrevers-
ible tissue damage and death of the whole animal. Therefore,
inhibition of RIP3 mediated necrosis with chemical inhibitors
has the possibility to treat acute or chronic inflammation-related
diseases such as pancreatitis.
EXPERIMENTAL PROCEDURES
Reagents
The Smac mimetic compound was synthesized as described previously
(Li et al., 2004). Cycloheximide, propidium iodide, LPS, hematoxylin and eosin
were obtained from Sigma. z-VAD and Q-VD-OPH were from Bachem and
Calbiochem, respectively. Necrostatin-1was purchased fromAlexis Biochem-
icals. Human TNF-a monoclonal antibody and recombinant mouse TRAIL
were from R&D Systems. Lambda Protein Phosphatase was from NEB.
Amylase assay kit was from BioAssay Systems. The following antibodies
were used for western blotting: RIPK1 (BD Biosciences, 610458), RIPK1
(Cell Signaling, 4926), Flag (Sigma, A8592), TNF-RI (Santa Cruz Biotech,
SC-8436), PARP (Cell Signaling, 9542), caspase-8 (Cell Signaling, 9746), cas-
pase-8 (BD Bioscience, 556466), mouse RIP3 (Prosci,XA-1023), FADD
(Stressgen, AAM-212E), cIAP2(BD,552783), cIAP1(R&D,AF8181) and GAPDH
(ab9486, Abcam). Human RIP3 polyclonal antibody was generated against
full-length human RIP3 recombinant protein. GST-TNF-a (human) was gener-
ated as in Wang et al., 2008. Recombinant human TRAIL protein was gener-
ated as previously described (Li et al., 2004) and recombinant human FasL
was from Axxora.
Cell Culture
Human colon cancer HT-29, pancreatic carcinoma Panc-1, glioblastoma
T98G, osteosarcoma U2OS, T cell leukemia CCRF-CEM, breast cancer
MCF-7, HEK293T and mouse fibrosarcoma L929 cells were obtained from
ATCC. Mouse embryonic fibroblasts (MEFs) were isolated from day 14.5-
15.5 embryos. Jurkat leukemia cells were kindly provided by Dr. Adrian Ting
of Mount Sinai School of Medicine and FADD null Jurkat was from ATCC.
H2009 and NCI-460 nonsmall cell lung carcinoma cells were gifts from the
laboratory of Dr. John Minna (UT Southwestern Medical Center at Dallas).
Cyclophilin D+/+ and Cyclophilin D/MEFs were kindly provided by Dr. Yosh-
ihide Tsujimoto of Osaka University. The culture conditions of these cells were
described in the Supplemental Data.
Plasmids and siRNA Oligoes
RIP3 cDNA was amplified by RT-PCR from total RNA of HT-29 cells with
primers containing a C-terminal HA epitope and then cloned into a modified
pCI-neo plasmid (Promega), which contains 3XFlag at the N-terminus. The
RIP3 mutant cDNA constructs, RIP3-shRNA constructs, and siRNA oligoes
were described in the Supplemental Data.Cell 137, 1100–1111, June 12, 2009 ª2009 Elsevier Inc. 1109
Cell Transfection and Immunofluorescent Staining
Transfection of cells with plasmid DNA or siRNA was performed according to
the procedures described previously (Wang et al., 2008). The transfection of
siRNA oligos to I2.1 Jurkat cells was performed using Amaxa machine as
described in Sun et al., 2004 (Supplemental References). For Figure S7,
Flag-RIP3 expression stable cells were transfected with pDsRed2-Mito,
pDsRed2-ER, pDsRed2-Peroxi, pDsRed-Golgi, pAcGFP1-Endo (Clontech)
or GFP-LAMP1. Thirty hours posttransfection, cells were treated as indicated
in figure legend and stained with mouse anti-flag antibody (Sigma). FITC-
conjugated or Rodamin-conjugated secondary antibody (Molecular Probe)
was used. Cells were examined under a confocal microscopy (Zeiss 510).
RNAi Screening Procedure
Human genome-wide siRNA screening and analysis were described in the
Supplemental Data.
Western Blot Analysis and Immunoprecipitation
The procedures for western blotting analysis and immunoprecipitation using
antibodies against Flag, RIPK1, and caspase-8 were described in the Supple-
mental Data.
Generation of Stable Cell Lines
To generate RIP3 kinase-dead mutant expression cells, linearized plasmid
DNA was transfected into HT-29 cells. Forty-eight hours post transfection,
the cells were cultured in complete medium containing 2 mg/ml G418 (Calbio-
chem). After 4 weeks, clones were tested for expression of the transgene. For
RIP3-shRNA expression cells, HT-29 cells were transfected with RIP3-shRNA
construct and selected with 0.5 mg/ml puromycin (Calbiochem). The shRNA-
resistant scramble wild-type or kinase-dead version of RIPK1 expression
construct was further introduced into RIP3-shRNA stable cells and colonies
were selected with 2 mg/ml G418.
Generation of RIP3 Knockout Mice
The RIP3 knockout mice were generated as described previously (Newton et
al, 2004) with minor modification (Figure S8). The procedure used was
described in the Supplemental Data.
Cerulein-Induced Pancreatitis
Male RIP3 deficient and wild-type littermate mice at 7-8 weeks of age were
given intraperitoneal injections of 50 mg/kg cerulein (Sigma) once every hour
for 10 hr. Animals were sacrificed 24 hr after the first injection and samples
of tissues and blood were rapidly harvested. Quantification of pancreas injury
was performed on pancreatic tissue sections stained with H&E and serum
amylase activity.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, Supple-
mental References, and twelve figures and can be found with this article online
at http://www.cell.com/supplemental/S0092-8674(09)00578-9.
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